HEAD & NECK CANCERS

Latest News

FDA Approves Tislelizumab for Unresectable or Metastatic ESCC
FDA Approves Tislelizumab for Unresectable or Metastatic ESCC

March 14th 2024

The FDA approved tislelizumab alone for patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy not including a PD-1/PD-L1 inhibitor.

FDA Fast Tracks 9MW2821 for Esophageal Squamous Cell Carcinoma
FDA Fast Tracks 9MW2821 for Esophageal Squamous Cell Carcinoma

February 28th 2024

Lidocaine May be a Valuable New Tool for Cancer Treatment
Lidocaine May be a Valuable New Tool for Cancer Treatment

December 13th 2023

FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy
FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

November 29th 2023

FDA Greenlights Toripalimab in Advanced Nasopharyngeal Carcinoma
FDA Greenlights Toripalimab in Advanced Nasopharyngeal Carcinoma

October 27th 2023

Video Series
Video Interviews

More News